Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
Open Access
- 1 January 2021
- journal article
- review article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 17 (2), 84-87
- https://doi.org/10.17925/ee.2021.17.2.84
Abstract
Type 2 diabetes mellitus (T2DM) affects an estimated 463 million people worldwide, equivalent to 1 in 11 adults. Moreover, the rapid growth of this disease has resulted in a high incidence of diabetic kidney disease (DKD), which, together with hypertension, is the main cause of chronic kidney disease (CKD). Hyperglycaemia, low-grade inflammation, altered lipid metabolism and hyperactivation of the renin-angiotensin-aldosterone system (RAAS) seem to be interrelated mechanisms contributing to both T2DM and microvascular complications. The introduction of drugs such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists has improved the ability to slow the progression of DKD, and has also demonstrated benefits in cardiovascular disease. Beyond the effects of these novel antidiabetic drugs, a body of evidence suggests that the overactivation of the mineralocorticoid receptor also contributes to CKD progression. Moreover, new and ongoing trials have demonstrated that the selective nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone improves the risk of CKD progression and cardiovascular events in patients with CKD and T2DM and optimized RAAS blockade. We review the rationale for the development and use of MRA drugs to slow CKD progression in patients with DKD, as well as other pleiotropic effects, and highlight the warnings associated with these agents.Keywords
Funding Information
- This article is published under the Creative Commons Attribution Non-commercial License.
This publication has 31 references indexed in Scilit:
- Diabetes 2030: Insights from Yesterday, Today, and Future TrendsPopulation Health Management, 2017
- Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney diseaseExpert Opinion on Investigational Drugs, 2015
- Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseaseEuropean Journal of Heart Failure, 2015
- Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney DiseaseJournal of the American Society of Nephrology, 2014
- Basic scienceJournal of the American Society of Hypertension, 2014
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathyFrontiers in Pharmacology, 2013
- Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF)European Journal of Heart Failure, 2012
- Aldosterone Antagonists for Preventing the Progression of Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionThe New England Journal of Medicine, 2003
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999